New pill shows promise against Hard-to-Treat cancers in early trial
NCT ID NCT06846099
First seen Jan 08, 2026 · Last updated May 02, 2026 · Updated 17 times
Summary
This early-stage study tested a new drug called RP903 in 69 people with advanced ovarian, breast, endometrial, cervical, or other solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it could shrink tumors. The drug targets a specific genetic change (PIK3CA mutation) that can fuel cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital of Fudan University
Shanghai, China
-
Affiliated Hospital of Jining Medical College
Jining, China
-
Beijing Cancer Hospital
Beijing, China
-
Ceneral Hosipital of Ningxia Medical University
Yinchuan, China
-
Chongqing University Cancer Hospital
Chongqing, China
-
Fujian Cancer Hospital
Fuzhou, China
-
Fujian Medical University Union Hospital
Fuzhou, China
-
Guangxi Medical University Cancer Hospital
Nanning, China
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Hubei Cancer Hospital
Wuhan, China
-
Jilin Cancer Hospital
Changchun, China
-
Jilin University First Hospital
Changchun, China
-
Liaoning Cancer Hospital&Institute
Shenyang, China
-
Linyi Cancer Hospital
Linyi, China
-
Shandong Cancer Hospital & Institute
Jinan, China
-
Sichuan Cancer Hospital
Chengdu, China
-
Sir Run Run Shaw Hospital
Hangzhou, China
-
Suining Central Hospital
Suining, China
-
The Affiliated Hospital of Qingdao University
Qingdao, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
-
Zhejiang Cancer Hospital
Hangzhou, China
Conditions
Explore the condition pages connected to this study.